| Title |
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
|
|---|---|
| Published in |
Cancer Immunology Research, November 2021
|
| DOI | 10.1158/2326-6066.cir-21-0454 |
| Pubmed ID | |
| Authors |
Amrita Basu, Gabriella K. Albert, Sabrina Awshah, Jashodeep Datta, Krithika N. Kodumudi, Corey Gallen, Amber Beyer, Keiran S.M. Smalley, Paulo C. Rodriguez, Derek R. Duckett, Peter A. Forsyth, Aixa Soyano, Gary K. Koski, Ricardo Lima Barros Costa, Heather Han, Hatem Soliman, Marie Catherine Lee, Pawel Kalinski, Brian J. Czerniecki |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 36% |
| Australia | 1 | 9% |
| Unknown | 6 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 73% |
| Scientists | 2 | 18% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 19% |
| Student > Bachelor | 3 | 19% |
| Student > Doctoral Student | 3 | 19% |
| Student > Master | 1 | 6% |
| Unknown | 6 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Medicine and Dentistry | 2 | 13% |
| Immunology and Microbiology | 1 | 6% |
| Chemistry | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 6 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2023.
All research outputs
#1,422,692
of 25,163,238 outputs
Outputs from Cancer Immunology Research
#136
of 1,511 outputs
Outputs of similar age
#28,651
of 391,498 outputs
Outputs of similar age from Cancer Immunology Research
#6
of 21 outputs
Altmetric has tracked 25,163,238 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,511 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.1. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 391,498 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.